287 related articles for article (PubMed ID: 15550582)
21. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
Ajani JA; Abramov M; Bondarenko I; Shparyk Y; Gorbunova V; Hontsa A; Otchenash N; Alsina M; Lazarev S; Feliu J; Elme A; Esko V; Abdalla K; Verma U; Benedetti F; Aoyama T; Mizuguchi H; Makris L; Rosati G;
Ann Oncol; 2017 Sep; 28(9):2142-2148. PubMed ID: 28911091
[TBL] [Abstract][Full Text] [Related]
22. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.
Bouché O; Raoul JL; Bonnetain F; Giovannini M; Etienne PL; Lledo G; Arsène D; Paitel JF; Guérin-Meyer V; Mitry E; Buecher B; Kaminsky MC; Seitz JF; Rougier P; Bedenne L; Milan C;
J Clin Oncol; 2004 Nov; 22(21):4319-28. PubMed ID: 15514373
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Assersohn L; Brown G; Cunningham D; Ward C; Oates J; Waters JS; Hill ME; Norman AR
Ann Oncol; 2004 Jan; 15(1):64-9. PubMed ID: 14679122
[TBL] [Abstract][Full Text] [Related]
25. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
Caroli-Bosc FX; Van Laethem JL; Michel P; Gay F; Hendlisz A; Forget F; Bleiberg H
Eur J Cancer; 2001 Oct; 37(15):1828-32. PubMed ID: 11576835
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO.
Kollmannsberger C; Budach W; Stahl M; Schleucher N; Hehr T; Wilke H; Schleicher J; Vanhoefer U; Jehle EC; Oechsle K; Trarbach T; Boehlke I; Kanz L; Hartmann JT; Bokemeyer C
Ann Oncol; 2005 Aug; 16(8):1326-33. PubMed ID: 15919686
[TBL] [Abstract][Full Text] [Related]
27. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
29. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Curran D; Pozzo C; Zaluski J; Dank M; Barone C; Valvere V; Yalcin S; Peschel C; Wenczl M; Goker E; Bugat R
Qual Life Res; 2009 Sep; 18(7):853-61. PubMed ID: 19568958
[TBL] [Abstract][Full Text] [Related]
30. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Ajani JA; Fodor MB; Tjulandin SA; Moiseyenko VM; Chao Y; Cabral Filho S; Majlis A; Assadourian S; Van Cutsem E
J Clin Oncol; 2005 Aug; 23(24):5660-7. PubMed ID: 16110025
[TBL] [Abstract][Full Text] [Related]
31. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
32. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
Comella P; Crucitta E; De Vita F; De Lucia L; Farris A; Del Gaizo F; Palmeri S; Lannelli A; Mancarella S; Tafuto S; Maiorino L; Buzzi F; De Cataldis G;
Ann Oncol; 2002 Jun; 13(6):866-73. PubMed ID: 12123331
[TBL] [Abstract][Full Text] [Related]
33. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G
Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
Samalin E; Afchain P; Thézenas S; Abbas F; Romano O; Guimbaud R; Bécouarn Y; Desseigne F; Edeline J; Mitry E; Bouché O; Adenis A; Aparicio T; Dorval E; Kramar A; Ychou M
Clin Res Hepatol Gastroenterol; 2011 Jan; 35(1):48-54. PubMed ID: 21634054
[TBL] [Abstract][Full Text] [Related]
35. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
[TBL] [Abstract][Full Text] [Related]
36. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
37. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.
Deleporte A; Van den Eynde M; Forget F; Holbrechts S; Delaunoit T; Houbiers G; Kalantari HR; Laurent S; Vanderstraeten E; De Man M; Vergauwe P; Clausse M; Van Der Auwera J; D'Hondt L; Pierre P; Ghillemijn B; Covas A; Paesmans M; Ameye L; Awada A; Sclafani F; Hendlisz A
Cancer Med; 2021 Jul; 10(13):4366-4374. PubMed ID: 34057299
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.
Bokemeyer C; Hartmann JT; Lampe CS; Clemens MR; Quietzsch D; Forkmann L; Kanz L
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-96-S19-100. PubMed ID: 9427277
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
[TBL] [Abstract][Full Text] [Related]
40. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Hofheinz R; Hartung G; Samel S; Emig M; Pilz L; Willeke F; Hochhaus A; Hehlmann R; Queisser W
Anticancer Drugs; 2002 Nov; 13(10):999-1004. PubMed ID: 12439333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
